Spreadsheet: 5be89a14-2cb5-4fc0-89b3-b2836119eb7c
Sheet: Featured Products

 |  | PharmaBiz(www.iPharmaBiz.com) (Please contact us for any inquiry) |  |  |  | Aug 08, 2011 updated
Country | INN | Indication | Strength | Dossier | Status | Remark | Original Brand | Originator
Greece | Rivastigmine | Dementia, Parkinson's disease | Capsules 1.5, 3, 4.5, 6mg Oral solution 2mg/ml | CTD | DCP procedure ended/ National approval is pending | 1)Non-infringing API: Launching possilbe now 2)Infringing API(cheaper): 7,8/2012 | Exelon | Novartis
Italy | Epoprostenol | Primary pulmonary hypertension | Injectable 0.5, 1.5mg | eCTD Dossier | DCP in Norway and Denmark ended/National approval is pending |  | Flolan | GSK
Italy | Exemestane | Breast cancer | Tablet 25mg | eCTD Dossier | Ongoing DCP |  | Aromasin | Pfizer
Italy | [NAME] | Skeletal fractures, Osteoporosis, [NAME] | 4mg/5ml | eCTD Dossier | Ongoing DCP |  | [NAME] | Novartis
Portugal | Eplerenone | Chronic Heart Failure | Film-coated tablets 25mg and 50mg | CTD Dossier ready | Under registration in Portugal and Spain |  | Inspra | Pfizer
Portugal | [NAME] | Anticonvulsant /Epilepsy | Film-coated tablets 250mg/ 500mg/ 750mg and 1000mg | CTD Dossiers ready | Products under registration in PT, SP and other EU countries |  | Keppra | UCB
Portugal | [NAME] | Anticonvulsant / Epilepsy | Oral solution 100mg/ml (300ml) | CTD Dossiers ready | Products under registration in PT, SP and other EU countries |  | Keppra | UCB
Portugal | Pregabaline | Anticonvulsant / Neuropathic pain | Capsules 300mg/ 225mg/ 200mg/ 150mg/ 100mg/ 75mg/ 50mg and 25mg | Product is under development. CTD Dossier expected 2Q 2012 | Not yet submitted. Submission only planned after dossier completion |  | Lyrica | Pfizer
Portugal | Sildenafil | Erectile dysfunction | Film-coated tablets 25mg/ 50mg and 100mg | CTD Dossier ready | Products comercialized in several EU countries |  | Viagra | Pfizer
Portugal | [NAME] | Skeletal fractures, Osteoporosis, [NAME] | Concentrated for solution for infusion 4mg/5ml | Product is under development. CTD Dossier expected 1Q 2012 | Not yet submitted. Submission only planned after dossier completion |  | [NAME] | Novartis
Portugal | [NAME] | Skeletal fractures, Osteoporosis, [NAME] | Solution for infusion 5mg/100ml | Product is under development. CTD Dossier expected 1Q 2012 | Not yet submitted. Submission only planned after dossier completion |  | [NAME] | Novartis
France | Zolmitriptan | Migraine/Selective agonist 5-HT receptor | 2.5, 5mg orodispersible tablet |  | Registered in Europe |  | Zomig | Astrazeneca
Greece | Desloratadine | Respiratory | Film-Coated  Tablet 5mg | CTD | Available |  | Aerius | Schering
Greece | Desloratadine | Respiratory | Oral Solution / 0.5mg/ml (30ml, 50ml, 60ml, 100ml, 120ml, 150ml, 225ml, 300ml) | CTD | Available
Greece | Desloratadine (ODT) | Respiratory | Orodispersible Tablet 2.5mg, 5mg | CTD | Available
Greece | Exemestane | Oncology | Film-Coated  Tablet 25mg | CTD | Available
Greece | Letrozole | Oncology | Film-coated tablet 2.5mg | CTD | Available
Greece | Rivastigmine | CNS | Hard Capsule 1.5mg, 3mg, 4.5mg, 6mg | CTD | Available
Greece | Sildenafil | Erectile Dysfunction | Chewable Tablet 25mg, 50mg, 100mg | CTD | Available
Greece | Sildenafil | Erectile Dysfunction | Film-coated tablet 25mg, 50mg, 100mg | CTD | Available
Greece | Ziprasidone | CNS | Hard Capsule 20mg, 40mg, 60mg, 80mg | Q3 2011